AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience

CareDx500 enrolled

Overview

The utilization of AlloSure to help guide immunosuppression management in solid organ transplant recipients diagnosed with COVID-19

An observational case series of patients with solid organ transplants who have been admitted with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression management balancing the treatment of sepsis and avoiding allograft rejection.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Solid Organ Transplant Rejection COVID-19

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed diagnosis of COVID-19 Exclusion Criteria:

Outcomes

Primary Outcomes

Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19

AlloSure dd-cfDNA blood draw values

Time frame: 6 months

Central Contacts

Alana Burns

CONTACT

415.287.2420 aburns@caredx.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.